Travere Therapeutics, Inc. is rated Buy with FILSPARI’s robust growth, FDA approval, and key milestones ahead. Click here to ...

Travere Therapeutics TVTX announced that the FDA, following further review of the supplemental new drug application (sNDA) ...

Learn more about whether ADMA Biologics, Inc. or Travere Therapeutics, Inc. is a better investment based on AAII's A+ ...

Learn more about whether Alvotech or Travere Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, ...

Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that following further review of the supplemental New Drug ...

Travere Therapeutics (TVTX) has witnessed significant developments, including the FDA's decision not to call an advisory committee meeting for the sNDA of FILSPARI®, while the drug is still under ...

Travere Therapeutics, Inc. (TVTX) shares are trading higher on Wednesday after the company announced that it was informed by ...

After Travere Therapeutics (TVTX) announced that the FDA informed the company it no longer plans to hold an advisory committee meeting to review ...

Travere Therapeutics (TVTX) stock climbs as the FDA skips advisory meeting in the review of a label expansion for the company ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company shared two oral presentations in classical homocystinuria (HCU) at the International Congress of Inborn Errors of Metabolism ...